Angela M. Moran
Sanjay Ramakrishnan, Edith Cowan UniversityFollow
Catherine A. Borg
Clare M. Connolly
Christine M. Mwasuku
Ian D. Pavord
Timothy S.C. Hinks
Letter to the Editor
American Journal of Respiratory and Critical Care Medicine
American Thoracic Society
School of Medical and Health Sciences
We thank Dr. Lipworth and colleagues for their interest in our work published recently in the Journal (1). They rightly point out that the biology of asthma attacks is more complex than blood eosinophils alone and that corticosteroids have a wide range of other potentially relevant antiinflammatory effects. However, local treatment with inhaled corticosteroids (ICS) is usually the mainstay of patients with frequent eosinophilic exacerbations, and therefore in the great majority of patients, the key question is what oral corticosteroids (OCS) add to ICS in an acute attack (2) and whether this effect is seen with benralizumab. We suggest that depletion of circulating eosinophils is the only effect OCS are likely to have that are not shared with ICS (3).
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Chemicals and Drugs Commons, Respiratory Tract Diseases Commons, Translational Medical Research Commons
Moran, A. M., Ramakrishnan, S., Borg, C. A., Connolly, C. M., Couillard, S., Mwasuku, C. M., … Lehtimӓki, L. (2020). Reply to Lipworth et al.: Don't forget about facilitatory effects of corticosteroids on β2-adrenoceptors in acute asthma. American Journal of Respiratory and Critical Care Medicine, 202(12), 1743-1744. https://doi.org/10.1164/rccm.202008-3106LE